{"id":17094,"date":"2024-10-16T04:53:50","date_gmt":"2024-10-16T04:53:50","guid":{"rendered":"https:\/\/expresorgv.online\/home\/?p=17094"},"modified":"2024-10-16T04:53:51","modified_gmt":"2024-10-16T04:53:51","slug":"cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado","status":"publish","type":"post","link":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/","title":{"rendered":"Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado"},"content":{"rendered":"\n<p>La Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris) aprob\u00f3 el uso de un <strong>nuevo tratamiento para el c\u00e1ncer de mama avanzado<\/strong> en personas adultas.<\/p>\n\n\n\n<p>Se trata de <strong>capivasertib<\/strong>, un medicamento que, en combinaci\u00f3n con fulvestrant, ser\u00e1 utilizado para combatir esta enfermedad <strong>en pacientes cuyo c\u00e1ncer reapareci\u00f3 o empeor\u00f3<\/strong> durante o despu\u00e9s de la terapia hormonal.<\/p>\n\n\n\n<p>Este tratamiento tiene como objetivo <strong>evitar la multiplicaci\u00f3n de c\u00e9lulas cancerosas<\/strong>, ofreciendo una opci\u00f3n adicional a los pacientes que enfrentan esta condici\u00f3n.<\/p>\n\n\n\n<p>Seg\u00fan un comunicado emitido por Cofepris, \u201ccapivasertib contribuye a diversificar las opciones terap\u00e9uticas disponibles para abordar esta grave condici\u00f3n\u201d, lo cual es especialmente relevante debido a que el c\u00e1ncer de mama es el tipo m\u00e1s frecuente de c\u00e1ncer a nivel mundial y<strong> la principal causa de muerte por esta enfermedad en mujeres.<\/strong><\/p>\n\n\n\n<p>Adem\u00e1s, la comisi\u00f3n se\u00f1ala que cerca del 85 por ciento de los casos se presenta en pacientes sin antecedentes familiares de esta enfermedad, subrayando la importancia de contar con tratamientos efectivos para una amplia gama de pacientes.<\/p>\n\n\n\n<p>El registro sanitario es parte de los 16 nuevos medicamentos reportados en el m\u00e1s reciente<strong> Informe quincenal de ampliaci\u00f3n terap\u00e9utica de Cofepris<\/strong>, correspondiente a la segunda quincena de septiembre. Este informe tambi\u00e9n incluy\u00f3 la autorizaci\u00f3n de 129 nuevos insumos para la salud, entre los que se encuentran seis ensayos cl\u00ednicos y 107 dispositivos m\u00e9dicos.<\/p>\n\n\n\n<p>Entre los dispositivos autorizados se destacan cat\u00e9teres gu\u00eda, sistemas de pr\u00f3tesis de cadera, pr\u00f3tesis de pene, injertos sint\u00e9ticos para regeneraci\u00f3n \u00f3sea y mallas quir\u00fargicas no absorbibles.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris) aprob\u00f3 el uso de un nuevo tratamiento para el c\u00e1ncer de mama avanzado en personas adultas. Se trata de capivasertib, un medicamento que, en combinaci\u00f3n con fulvestrant, ser\u00e1 utilizado para combatir esta enfermedad en pacientes cuyo c\u00e1ncer reapareci\u00f3 o empeor\u00f3 durante o despu\u00e9s de la [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":17066,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-17094","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nacional"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado\" \/>\n<meta property=\"og:description\" content=\"La Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris) aprob\u00f3 el uso de un nuevo tratamiento para el c\u00e1ncer de mama avanzado en personas adultas. Se trata de capivasertib, un medicamento que, en combinaci\u00f3n con fulvestrant, ser\u00e1 utilizado para combatir esta enfermedad en pacientes cuyo c\u00e1ncer reapareci\u00f3 o empeor\u00f3 durante o despu\u00e9s de la [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-16T04:53:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-16T04:53:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png\" \/>\n\t<meta property=\"og:image:width\" content=\"540\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"expreso\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"expreso\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/\"},\"author\":{\"name\":\"expreso\",\"@id\":\"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2\"},\"headline\":\"Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado\",\"datePublished\":\"2024-10-16T04:53:50+00:00\",\"dateModified\":\"2024-10-16T04:53:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/\"},\"wordCount\":288,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png?fit=540%2C300&ssl=1\",\"articleSection\":[\"NACIONAL\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/\",\"url\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/\",\"name\":\"Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado -\",\"isPartOf\":{\"@id\":\"https:\/\/expresorgv.online\/home\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png?fit=540%2C300&ssl=1\",\"datePublished\":\"2024-10-16T04:53:50+00:00\",\"dateModified\":\"2024-10-16T04:53:51+00:00\",\"author\":{\"@id\":\"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2\"},\"breadcrumb\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#primaryimage\",\"url\":\"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png?fit=540%2C300&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png?fit=540%2C300&ssl=1\",\"width\":540,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/expresorgv.online\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/expresorgv.online\/home\/#website\",\"url\":\"https:\/\/expresorgv.online\/home\/\",\"name\":\"\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/expresorgv.online\/home\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2\",\"name\":\"expreso\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g\",\"caption\":\"expreso\"},\"url\":\"https:\/\/expresorgv.online\/home\/blog\/author\/expreso\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/","og_locale":"es_ES","og_type":"article","og_title":"Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado","og_description":"La Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris) aprob\u00f3 el uso de un nuevo tratamiento para el c\u00e1ncer de mama avanzado en personas adultas. Se trata de capivasertib, un medicamento que, en combinaci\u00f3n con fulvestrant, ser\u00e1 utilizado para combatir esta enfermedad en pacientes cuyo c\u00e1ncer reapareci\u00f3 o empeor\u00f3 durante o despu\u00e9s de la [&hellip;]","og_url":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/","article_published_time":"2024-10-16T04:53:50+00:00","article_modified_time":"2024-10-16T04:53:51+00:00","og_image":[{"width":540,"height":300,"url":"https:\/\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png","type":"image\/png"}],"author":"expreso","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"expreso","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#article","isPartOf":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/"},"author":{"name":"expreso","@id":"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2"},"headline":"Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado","datePublished":"2024-10-16T04:53:50+00:00","dateModified":"2024-10-16T04:53:51+00:00","mainEntityOfPage":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/"},"wordCount":288,"commentCount":0,"image":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png?fit=540%2C300&ssl=1","articleSection":["NACIONAL"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/","url":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/","name":"Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado -","isPartOf":{"@id":"https:\/\/expresorgv.online\/home\/#website"},"primaryImageOfPage":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#primaryimage"},"image":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png?fit=540%2C300&ssl=1","datePublished":"2024-10-16T04:53:50+00:00","dateModified":"2024-10-16T04:53:51+00:00","author":{"@id":"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2"},"breadcrumb":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#primaryimage","url":"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png?fit=540%2C300&ssl=1","contentUrl":"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png?fit=540%2C300&ssl=1","width":540,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/10\/16\/cofepris-autoriza-nuevo-tratamiento-para-el-cancer-de-mama-avanzado\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/expresorgv.online\/home\/"},{"@type":"ListItem","position":2,"name":"Cofepris autoriza nuevo tratamiento para el c\u00e1ncer de mama avanzado"}]},{"@type":"WebSite","@id":"https:\/\/expresorgv.online\/home\/#website","url":"https:\/\/expresorgv.online\/home\/","name":"","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/expresorgv.online\/home\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2","name":"expreso","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g","caption":"expreso"},"url":"https:\/\/expresorgv.online\/home\/blog\/author\/expreso\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/10\/161024CancerMama.png?fit=540%2C300&ssl=1","_links":{"self":[{"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/posts\/17094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/comments?post=17094"}],"version-history":[{"count":1,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/posts\/17094\/revisions"}],"predecessor-version":[{"id":17095,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/posts\/17094\/revisions\/17095"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/media\/17066"}],"wp:attachment":[{"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/media?parent=17094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/categories?post=17094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/tags?post=17094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}